Surrogate Endpoints and Drug Regulation: What Is Needed to Clarify the Evidence

, , , &
Journal of Law, Medicine and Ethics 47 (3):381-387 (2019)
  Copy   BIBTEX

Abstract

The FDA's new table of surrogate endpoints used for drug approvals is an important step forward for overseeing the use of biomarkers in clinical trials. Nevertheless, we present several ways in which the table can be improved.

Categories

Keywords

Reprint years

DOI

10.1177/1073110519876167

Other Versions

No versions found

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 103,567

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

My notes

Similar books and articles

Biomarkers as Surrogate Endpoints: Ongoing Opportunities for Validation.Audrey D. Zhang & Joseph S. Ross - 2019 - Journal of Law, Medicine and Ethics 47 (3):393-395.
Cochrane's Linked Data Project: How it Can Advance our Understanding of Surrogate Endpoints.Chris Mavergames, Deirdre Beecher, Lorne A. Becker, A. Last & A. Ali - 2019 - Journal of Law, Medicine and Ethics 47 (3):374-380.
Battles Over Medication Abortion Threaten the Integrity of Drug Approvals in the U.S.Liam Bendicksen & Aaron S. Kesselheim - 2023 - Journal of Law, Medicine and Ethics 51 (2):448-449.
Aducanumab, Accelerated Approvals & the Agency: Why the FDA Needs Structural Reform.Matthew Herder - 2023 - Journal of Law, Medicine and Ethics 51 (4):900-919.
Ethical challenges of clinical trials with a repurposed drug in outbreaks.Katarzyna Klas, Karolina Strzebonska & Marcin Waligora - 2023 - Medicine, Health Care and Philosophy 26 (2):233-241.
Robust Biomarkers: Methodologically Tracking Causal Processes in Alzheimer’s Measurement.Vadim Keyser & Louis Sarry - 2020 - In Barbara Osimani & Adam La Caze, Uncertainty in Pharmacology. pp. 289-318.
Robust Biomarkers: Methodologically Tracking Causal Processes in Alzheimer’s Measurement.Vadim Keyser & Louis Sarry - 2020 - In Barbara Osimani & Adam La Caze, Uncertainty in Pharmacology.
Great Trees Require Strong Roots: Evaluating Data and Delegation Doctrine Underlying Proposed Reforms to FDA’s Accelerated Approval Program.Anjali D. Deshmukh - 2023 - Journal of Law, Medicine and Ethics 51 (4):920-925.
Translating Stem Cell Research: Challenges at the Research Frontier.David Magnus - 2010 - Journal of Law, Medicine and Ethics 38 (2):267-276.
Umbrella and basket trials in oncology: ethical challenges.Karolina Strzebonska & Marcin Waligora - 2019 - BMC Medical Ethics 20 (1):1-10.

Analytics

Added to PP
2019-09-28

Downloads
25 (#937,108)

6 months
5 (#756,320)

Historical graph of downloads
How can I increase my downloads?

Author's Profile

Spencer Hey
Harvard University

Citations of this work

Biomarker Validation: Context and Complexities.Lisa M. McShane - 2019 - Journal of Law, Medicine and Ethics 47 (3):388-392.

Add more citations

References found in this work

No references found.

Add more references